# Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

> **NCT02170935** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 62 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** BIBR 1048 capsule

## Key facts

- **NCT ID:** NCT02170935
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2002-06
- **Final completion:** —
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2014-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170935, "Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02170935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*